Your browser does not allow JavaScript!
JavaScript is necessary for the proper functioning of this website. Please enable JavaScript or use a modern browser.
Open Science Slovenia
Open Science
DiKUL
slv
|
eng
Search
Browse
New in RUL
About RUL
In numbers
Help
Sign in
Non-animal glioblastoma models for personalized treatment
ID
Zottel, Alja
(
Author
),
ID
Jovchevska, Ivana
(
Author
),
ID
Šamec, Neja
(
Author
)
PDF - Presentation file,
Download
(2,11 MB)
MD5: 0FE6347909E948C36AB99DF4CCE276BC
URL - Source URL, Visit
https://www.sciencedirect.com/science/article/pii/S2405844023082786
Image galllery
Abstract
Glioblastoma is an extremely lethal cancer characterized by great heterogeneity at different molecular and cellular levels. As a result, treatment options have moved far from systemic and universal therapies toward targeted treatments and personalized medicine. However, for successful translation from preclinical studies to clinical trials, experiments must be performed on reliable disease models. Numerous experimental models have been developed for glioblastoma, ranging from simple 2D cell cultures to study the nature of the disease to complex 3D models such as neurospheres, organoids, tissue-slice cultures, bioprinted models, and tumor on chip, as perfect prototypes to evaluate the therapeutic potential of different drugs. The presence of multiple research models is consistent with the complexity and molecular diversity of glioblastoma. The advantage of such models is the recapitulation of the tumor environment, and in some cases the preservation of immune system components as well as the creation of simple vessels. There are also two case studies translating in vitro studies on glioblastoma organoids to patients as well as four ongoing clinical trials using glioblastoma models, indicating high clinical potential of glioblastoma models.
Language:
English
Keywords:
glioblastoma
,
heterogeneity
,
non-animal models
,
treatmet predicition
Work type:
Article
Typology:
1.02 - Review Article
Organization:
MF - Faculty of Medicine
Publication status:
Published
Publication version:
Version of Record
Year:
2023
Number of pages:
9 str.
Numbering:
Vol. 9, iss. 10, art. e21070
PID:
20.500.12556/RUL-152948
UDC:
616-006:577.2
ISSN on article:
2405-8440
DOI:
10.1016/j.heliyon.2023.e21070
COBISS.SI-ID:
170364419
Publication date in RUL:
13.12.2023
Views:
373
Downloads:
31
Metadata:
Cite this work
Plain text
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Copy citation
Share:
Record is a part of a journal
Title:
Heliyon
Publisher:
Elsevier
ISSN:
2405-8440
COBISS.SI-ID:
21607432
Licences
License:
CC BY-NC-ND 4.0, Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Link:
http://creativecommons.org/licenses/by-nc-nd/4.0/
Description:
The most restrictive Creative Commons license. This only allows people to download and share the work for no commercial gain and for no other purposes.
Secondary language
Language:
Slovenian
Keywords:
glioblastom
,
heterogenost
,
neživalski modeli
,
napoved zdravljenja
Projects
Funder:
ARRS - Slovenian Research Agency
Project number:
Z3-2649
Name:
Določitev novih biomarkerjev glioblastoma za namen neinvazivne tekočinske biopsije
Funder:
ARRS - Slovenian Research Agency
Project number:
Z3-4510
Name:
Vpliv imunoterapije z anti-PD-L1 atezolizumabom in nanotelesom Nb202 na organoide glioblastoma, pripravljene iz tkiva bolnikov
Funder:
ARRS - Slovenian Research Agency
Project number:
P1-0390
Name:
Funkcijska genomika in biotehnologija za zdravje
Funder:
Other - Other funder or multiple funders
Funding programme:
CELSA
Name:
Generation of nanobodies against immunomodulating checkpoint receptors in glioblastoma tumor cells
Similar documents
Similar works from RUL:
Similar works from other Slovenian collections:
Back